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Abstract
OBJECTIVE: To assess the safety and effectiveness
of Dengzhanxixin injection (DZI) extracted from
Dengzhanxixin (Herba Erigerontis Breviscapi) and
identify its potential risks.
METHODS: A series of studies were conducted on
the production process, quality standards, and
pharmacology. Postmarketing clinical studies and
literature reviews including adverse reactions
(ADR) ,adverse events (ADE), case analysis and sys-
tematic reviews were also conducted. Data from
the hospital information system and spontaneous
reporting system were analyzed.
RESULTS: The acute toxicity test indicated that the
Lethal Dose 50 test ( LD 50 ) dosage was 250 times
more than the clinical maximum daily dosage (6
mg/kg). In long-term toxicity tests, rats experi-
enced renal tubular damage at 480 mg/kg. Howev-
er, the dose of 120 mg/kg is safe and non-toxic,
which is 40 times above the clinical daily maxi-
mum. Beagles had increased serum creatinine at
160 mg/kg. In a prospective study, 15 962 cases ex-
perienced 16 ADR/ADE. The rate of ADR/ADE was
0.1002% . ADR symptoms included rash (16.00% ),
chills (16.00%), and fever (16.00%).
CONCLUSION: There is significant evidence that
DZI is safe and effective in a clinical setting.
© 2015 JTCM. All rights reserved.
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INTRODUCTION
Dengzhanxixin injection (DZI), manufactured by Yun-
nan Biovalley Pharmaceutical Co., Ltd., (YBPC) under
Approval No. G.Y.Z.Z. Z53021569, is a sterile aque-
ous injection made from active ingredients like pheno-
lic acids. These compounds are extracted from Deng-
zhanxixin (Herba Erigerontis Breviscapi), which is a me-
dicinal plant grown in Yunnan province. Dengzhanxix-
in (Herba Erigerontis Breviscapi) mainly contains scutel-
larin (C21H18O12) and various isomers of caffeic acid es-
ter (C25H24O12). DZI can activate blood, remove stasis,
dredge meridians, and alleviate pain, and is parenteral-
ly administered to treat ischemic stroke and angina pec-
toris in coronary heart disease (CHD). To assess wheth-
er it is safe and effective in clinic, and to identify its po-
tential risk factors, YBPC has carried out a series of
studies on DZI. These studies include its production
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process, quality standards and pharmacology, postmar-
keting clinical studies, and postmarketing safety evalu-
ation.
QUALITY CONTROL
The raw material for DZI is the whole plant of Deng-
zhanxixin (Herba Erigerontis Breviscapi). YBPC has es-
tablished a Good Agricultural Practices (GAP) base in
Mile county of Yunnan province as required by China
Food and Drug Administration to plant, harvest, pro-
cess, and store the raw material in accordance with
GAP. The suppliers of the raw material have been certi-
fied in accordance with GAP, and they are qualified for
planting and sales. The solution contains two active in-
gredients: flavonoids and caffeic acid esters. For the
raw material, YBPC not only controlled the content of
scutellarin in accordance with the Chinese Pharmaco-
poeia 2010: Part Ⅰ, but also developed more stringent
indicators for internal control. In addition to the scutel-
larin content required to meet the relevant require-
ment, the content of total caffeic acid esters was con-
trolled through Ultraviolet-visible spectroscopy spectro-
photometry. The raw material is not used for produc-
tion of the injection unless the content of the two in-
gredients is adequate.1
In the production process of DZI, the important steps
are the extraction of raw material and solution prepara-
tion. Therefore, YBPC detailed the column technology
so that toxic pyromeconic acid was fully eluted to re-
tain the active ingredients. A total of eight control
points were set for extraction, separation, and purifica-
tion. Online or offline analyses of chemical and physi-
cal indicators for these eight control points are conduct-
ed. High-performance liquid chromatography (HPLC)
and fingerprints are analyzed during the extraction-sep-
aration process to control ingredient content and yield.
During solution preparation, a refined preparation is
conducted with respect to the nature of the caffeic acid
esters. The sterile process involves incomplete steriliza-
tion, sterilizing filtration, and nitrogen protection to
ensure that the products are sterile.
Non-clinical safety and pharmacological study
In October 1999, YBPC entrusted Tianjin Institute of
Pharmaceutical Research (Tianjin, China) to conduct a
non-clinical safety and pharmacological study on the
acute, long-term, and special toxicology of DZI, as
well as a general pharmacological study. The results are
as follows:
Acute toxicity test: the acute toxicity test indicated that
mice had reduced activity, inactivity, polypnea, and lip
and tail cyanosis, followed by behavioral disorder, con-
vulsions, startling and eventual death after receiving
DZI through single doses of intravenous (IV) or intra-
peritoneal (IP) injection. The female and male Lethal
Dose 50 test (LD50) for IV DZI was 1676.75 and
1740.76 mg/kg, respectively, with no significant differ-
encebetweensexes.TheIPLD50ofDZIwas1770.92 mg/
kg, which was equivalent to more than 250 times the
maximum daily dosage (6 mg/kg) used in clinical appli-
cations.
Long-term toxicity test: for long-term toxicity tests,
rats were administered 30, 120, and 480 mg/kg of
DZI through IP injection once a day for 2 months.
General drug reactions were observed, and hematologi-
cal, blood biochemical, and histopathology indexes
were examined. A slow increase in body weight was ob-
served in the male rats in the 480 mg/kg dose group.
Pathological examination revealed mild opacity and
swelling in the renal tube epithelium of cortex in renal
tissue. No obvious changes or damage associated with
the drug were found in the 120 and 30 mg/kg dose
groups, and no delayed toxicity was found during the
2-week recovery after withdrawal of the drug. This in-
dicates that the 120 mg/kg dose of DZI was not toxic
for rats. This dosage is equivalent to more than
40 times the maximum daily dose (6 mg/kg) used in
clinical applications.
The results of the long-term toxicity test on Beagle
dogs showed that the adverse reactions of the animals
in the 160 mg/kg dose group during the 60-day contin-
uous venous infusion of DZI included obvious drool-
ing, extended tongue, nausea, and vomiting. Symp-
toms after administration included immediate loss of
appetite, procumbent stance, reduced activity, and
slower breathing and heart rate. Blood biochemical ex-
amination revealed increases in the level of creatinine
on the 30th day of administration. During administra-
tion, adverse reactions such as drooling, extended
tongue, nausea, and vomiting were found in some ani-
mals in the 40 mg/kg dose group, and there was only
one animal with a reaction equivalent to that of ani-
mals in the 160 mg/kg dose group. Animals receiving
the drug remained procumbent and lethargic after ad-
ministration, and the blood biochemical examination
revealed increases in total protein after administration.
No significant influences on animals' spirits, behavior,
diet, excrement, body weight, and urine biochemical
indicators were seen in the 10 mg/kg dose group. Com-
pared with the control group, no significant changes
were found in hematological examination, blood bio-
chemical examination, ophthalmologic examination,
electrocardiography, and bone marrow examination in
the 10 mg/kg group. Therefore, 10 mg/kg was the level
at which no adverse effects were observed.
Special toxicology tests: DZI was injected IV into rab-
bits via ear veins once a day for 3 days. No obvious irri-
tation effect was observed at the injection sites. Hemo-
lysis tests showed no hemolysis. DZI was injected IP in-
to guinea pigs once every other day, three times. No
positive allergic reactions were found after intravenous
injection of the drug on the 14th and 21st day after
first administration.
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General pharmacologic study: a dose of 4 mg/kg DZI
was IV injected into rats. Compared with the control
group, behavior disorder from cerebral ischemia caused
by ferric chloride was significantly improved by reduc-
ing the infarct area. Cerebral blood flow of rats suffer-
ing from microcirculatory disturbance from high-mo-
lecular dextran was significantly improved by reducing
blood viscosity of model rats. Further, the thrombus
formation time of normal rats was remarkably delayed
and platelet aggregation rate was reduced after adminis-
tration of IV DZI.
Treatment of ischemia and hemodynamics: a dose of
4 mg/kg DZI was injected IV into Beagle dogs. Com-
pared with the control group, the degree of acute isch-
emia in dogs with a ligated left anterior descending ar-
tery was significantly improved. Therefore, DZI can re-
duce the myocardial infarction area. The results of car-
diac hemodynamic tests on anaesthetized open-chest
dogs indicated that a certain dose of DZI could reduce
blood pressure, left ventricle pressure (LVP), maximum
LVP rate, left ventricle work, and coronary resistance,
while having no remarkable influence on heart rate,
left ventricular end-diastolic pressure, total peripheral
resistance, cardiac function, and other hemodynamic
parameters. Therefore, DZI has an anti-myocardial
ischemia effect by relieving cardiac after-load, expand-
ing the coronary arteries and peripheral vasculature,
and reducing returned blood volume and cardiac work.2
Postmarketing clinical study
A multi-center randomized controlled trial of DZI in
the treatment of acute ischemic stroke: from June
2008 to June 2010, relying on Study on Traditional
Chinese Medicine Schemes for Early Recovery from
and Recurrence Prevention of Ischemic Strokes (No.
2007AA02Z4B2), an 863 Program of the Ministry of
Science and Technology led by Wang Yongyan and re-
searcher Xie Yanming from the Institute of Basic Re-
search in Clinical Medicine, China Academy of Chi-
nese Medical Sciences, YBPC conducted a multi-center
randomized controlled clinical study on the treatment
of acute ischemic strokes with DZI. This study in-
volved 13 centers nationwide, in which a central ran-
domized system for clinical study was applied. Patients
were randomized into a DZI (Dengzhan group) and
Western medicine group (WM group). There were 343
cases in the Dengzhan group and 335 cases in the WM
group. The Dengzhan group included DZI with basic
therapy with Western internal medicine and the recov-
ery techniques of Traditional Chinese Medicine
(TCM). Clinical safety evaluation mainly involved ob-
serving laboratory examination indicators, adverse
events, and their incidences. In the Dengzhan group,
11 adverse drug reactions/events (ADR/ADE) oc-
curred, of which four cases were associated with DZI
based on a causal relationship, with the incidence of
ADRs being 1.17% (4/343). The symptoms of ADRs
included fever, chills, rash, nausea, dizziness, and palpi-
tations, and no serious ADRs occurred.3
Registry-based postmarketing clinical safety monitor-
ing study: the project "Registry-based postmarketing
clinical safety monitoring study of DZI" comes from
the Study on Key Technologies of Postmarketing Evalu-
ation of Chinese Medicine (No. 2009ZX09502-030),
a national science and technology major project "Ma-
jor New Drug Development" presided over by Yan-
ming Xie, researcher from the Institute of Basic Re-
search in Clinical Medicine, China Academy of Chi-
nese Medical Sciences. A total of 30 000 cases are ex-
pected to enroll in this study. In March 2012, the
study was approved by the ethics review board of the
institute (Approval No. 9-1) and the protocol registra-
tion was completed at ClinicalTrials. gov (ID:
NCT01612585). Monitoring has been initiated in 42
sub-centers of six hospitals: Jiangsu Provincial TCM
Hospital, Guangdong Provincial TCM Hospital, the
First Affiliated Hospital of Henan University of TCM,
Affiliated Hospital of Shandong University of Tradi-
tional Chinese Medicine, General Hospital of Tianjin
Medical University, and General Hospital of Ningxia
Medical University. Level-3 quality control was prac-
ticed in the project. From May to June 2013, three of
the lead hospitals (the Second Affiliated Hospital of
Guangzhou TCM University, Affiliated Hospital of
Shandong University of Traditional Chinese Medicine,
and Jiangsu TCM Hospital) received the first round of
level-3 auditing. The audit experts carefully checked
the qualifications of the monitored hospitals, research
staff, monitoring tables, and original information and
data to locate problems and summarize on-site audit
opinions on the monitored hospitals. By November
2013, 15 962 cases were enrolled in monitoring, with
16 ADR/ADE cases being reported. The ADR rate was
0.1002%. ADR symptoms included: rash (eight cases/
50% ), chills (two cases/12.5% ), fever (one case/
6.25%), shortness of breath (one case/6.25%), palpita-
tion (one case/6.25% ), headache (one case/6.25% ),
lower extremity edema (one case/6.25% ), elevated
blood pressure (one case/6.25%), and abdominal pain
(one case/6.25%).
Spontaneous reporting system (SRS) data analysis: data
mining analysis and early warning signals detection
were conducted with the proportional reporting ratio
(PRR) and Bayesian confidence propagation neural net-
work methods (BCPNN) using ADR reports on DZI
in the SRS database of the State Adverse Drug Reac-
tion Monitoring Center.4 The results showed that,
among the 1390 ADR reports, there were 71 reports
on serious ADRs, accounting for 5.11%. The frequen-
cy of ADRs for men was higher than that for women.
Most serious ADRs occurred in elderly patients aged
60 and over (64.03%). The top 10 ADR symptoms in-
cluded pruritus, rash, dizziness, chills, palpitation,
headache, fever, suffocation, nausea, and flush. The
most common systems and organs involved in ADR
were "damage to skin and its accessory organs" (551 in-
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stances). After confounding factors were controlled for
with the propensity score, the PRR and BCPNN meth-
ods both showed that headache, dizziness, palpitation,
and chills were early warning signals of adverse reac-
tions to DZI. These ADR symptoms were found in the
specifications of DZI, while suffocation, nausea, aller-
gies, and vomiting, which clinically occurred at a high
frequency, were not found in the drug instructions. Al-
though no early warning signals were well defined, par-
ticular attention should be paid to these symptoms dur-
ing clinical use.
Hospital information system (HIS) data analysis
Data from the HIS of 20 hospitals across China were
used to conduct clinical safety and effectiveness analy-
sis of DZI.
Total population descriptive analysis: of the 21 498 pa-
tients, those aged 45-80 accounted for 78%, and there
were more male patients than female patients. In most
patients, the dose was 30-40 mL each time, and the
treatment cycle was 8-12 days, which basically falls
within the range specified in the manufacturer's direc-
tions for DZI. DZI was given to 95.51% of patients
within 3 days after hospitalization. Common concomi-
tant medications were atorvastatin, probucol, and aspi-
rin for cerebral infarction, and metoprolol, aspirin, and
isosorbide dinitrate for coronary heart disease.5
Outcome analysis of DZI in the treatment of cerebral
infarction: a total of 2512 cases of cerebral infarction
were divided into an observation (given DZI) and con-
trol group (1008 and 1504, respectively), with mortali-
ty as the outcome. Using generalized boosted models
(GBM) to score weighted regression on age, gender,
and a database of 72 variables to be balanced, there
were significant differences in the observed group and
the control group (P < 0.001), suggesting that DZI
may reduce the death rate in patients with cerebral in-
farction.6
The influence of Erigeron injection on coronary heart
disease outcomes: a total of 2325 cases of coronary
heart disease were divided into an observation (given
DZI) and control group (768 and 1557, respectively).
Using GBM to score weighted regression on age, gen-
der, and a database of 72 variables to be balanced,
three kinds of logistic regression analyses were applied
to find the cure rate and mortality of coronary heart
disease. After controlling for confounders, there was a
significant difference in the cure rate and mortality rate
between the two groups, which indicated that the com-
bined use of DZI might improve the cure rate, and re-
duce the mortality of patients with coronary heart dis-
ease.7,8
Literature review: cross search was used to search the
Chinese Biomedical Literature Service System
(SinoMed), Wanfang Database, China National Knowl-
edge Infrastructure Database and China Science &
Technology Journal Database (from inception to
March 15, 2012). A total of 732 articles about DZI
were retrieved.
ADR case analysis: thirty articles concerned the safety
of DZI. After eliminating three duplicate articles, 11
articles concerning drug incompatibility, and one arti-
cle involving clinical safety cases, there were 15 articles
reporting individual cases, in which 25 cases were in-
volved. The 25 case reports involved 18 serious ADR
cases with no deaths. The ADRs included 10 cases of
anaphylactic shock, two cases of acute kidney failure,
four cases of abnormal liver function, one case of auric-
ular premature beat, and one case of bronchial asthma.
Of these 25 cases, the latest ADR occurred 10 days af-
ter continuous infusion, and the earliest ADR occurred
3 min after infusion began. The review found that the
common symptoms of adverse reactions to DZI as re-
ported in the literature were fever, chills, rash, nausea,
palpitation, and dizziness.9
Systematic reviews: a total of 17 randomized controlled
trials were incorporated into a meta-analysis on treating
unstable angina with DZI. The treatment effects on un-
stable angina in two groups were reported in 16 stud-
ies. The DZI treatment group included 765 patients
and the control group included 727 patients. The het-
erogeneity test resulted in P = 0.11 and I 2 = 32%. A
fixed effect model was used to carry out the Meta-analy-
sis. The treatment effects in the treatment group were
better than those in the control group, and the differ-
ence was statistically significant (P < 0.00 001). Fifteen
studies reported treatment effects in terms of electrocar-
diograms for the two groups. The DZI treatment
group included 784 patients and the control group in-
cluded 740 patients. The heterogeneity test resulted in
P = 0.15 and I 2 = 28%. Fixed effect model analysis
was used, revealing that the treatment effects in the
treatment group were better than those in the con-
trol group in terms of electrocardiograms. The differ-
ence was statistically significant (P < 0.000 01).
Therefore, the treatment of unstable angina by com-
bining DZI with ordinary therapy was better than
that of treatment with ordinary therapy alone. How-
ever, considering the differing quality among studies
and possible difficulty in publishing papers reporting
negative results, publication bias is possible in the re-
sults of the study.10
CONCLUSION
Since the involvement of DZI in the project "Regis-
try-based Clinical Safety Monitoring Study of Paren-
terally Administered Chinese Medicine," the follow-
ing have been published: a literature review report,
one systematic evaluation report, one HIS statistical
analysis report, one ADR analysis report, and one au-
dit report on DZI. There have also been 10 academ-
ic papers published related to the injection. This
study summarizes the significant evidence for the
safety and effectiveness of the injection in clinical
practice.
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